RBF Capital’s VistaGen Therapeutics VTGN Stock Holding History

RBF Capital’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-833	Closed	-$17K	–	410
2020 Q3	$17K	Hold	833	–	–	﹤0.01%	371
2020 Q2	$13K	Buy	+833	New	+$11.4K	﹤0.01%	389
2020 Q1	–	Sell	-833	Closed	-$19K	–	411
2019 Q4	$19K	Hold	833	–	–	﹤0.01%	385
2019 Q3	$27K	Hold	833	–	–	﹤0.01%	380
2019 Q2	$18K	Hold	833	–	–	﹤0.01%	392
2019 Q1	$32K	Hold	833	–	–	﹤0.01%	381
2018 Q4	$38K	Hold	833	–	–	0.01%	392
2018 Q3	$36K	Hold	833	–	–	﹤0.01%	405
2018 Q2	$35K	Buy	+833	New	+$29K	﹤0.01%	391

Other funds holding VTGN

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

RBF Capital's VTGN Position: Q4 2020 in Review

RBF Capital sold out of VistaGen Therapeutics (VTGN) in Q4 2020, closing a stake of 833 shares — an estimated $17K sold.

RBF Capital first reported a position in VTGN in Q2 2018 and held it in 9 quarters. The position peaked at $38K in Q4 2018. 52 funds tracked by Wall St. Rank hold VTGN as of Q4 2020.

RBF Capital reported no remaining VistaGen Therapeutics position as of Q4 2020 after selling out during the quarter.
RBF Capital sold 833 VistaGen Therapeutics shares in Q4 2020, an estimated $17K.
RBF Capital first reported a position in VistaGen Therapeutics in Q2 2018 and held it in 9 quarters.
RBF Capital's VistaGen Therapeutics position peaked at $38K in Q4 2018.
52 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q4 2020.

Based on RBF Capital's 13F filing for Q4 2020, filed 11 Feb 2021.